Age, Comorbid Conditions, FACT-TOI Scores, Gender, Particularly Rural/Urban Residence
Conditions
Brief summary
Our long-term goal is to integrate non-small cell lung cancer patient treatment preferences into clinical treatment planning.
Detailed description
The following specific aims are proposed: Aim 1: Determine whether individual patients' preferences, characteristics, and treatment experiences affect the definition of treatment success. Aim 2: Determine how to best predict real-life patients' treatment choices based on patients' preferences of adverse events. Aim 3: Determine whether physicians are likely to change their oncologic clinical practice after receiving a detailed communication of their patients' preferences of adverse events.
Interventions
None listed
Sponsors
Patient-Centered Outcomes Research Institute
University of Nebraska
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Willing and able to provide consent * Greater than or equal to 19 years of age * Diagnosed with stage IV non-small cell lung cancer (NSCLC) * Able to understand spoken English * Eligible to undergo chemotherapy for stage IV NSCLC, to include, but not limited to, those who: 1. have not yet started chemo 2. are currently undergoing chemo for stage IV NSCLC 3. have completed first line stage IV NSCLC chemo or progressed to maintenance for stage IV NSCLC within the last 30 days 4. elect to have chemo elsewhere -- not at one of the study sites 5. decline chemo
Exclusion criteria
* Age \<19 years * Not willing and/or able to provide consent * Not able to understand spoken English * Not eligible to undergo chemotherapy for stage IV NSCLC
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient-defined treatment success | Baseline | In advanced stage NSCLC patients does patient-defined treatment success differ when both survival and patient preferences of adverse events are accounted for, compared to when success is measured solely by survival? And does it also differ based on individual patient characteristics? |
| Patients' will to experience adverse events | Baseline | Will the serious adverse events that an advanced stage NSCLC patient is willing to experience as part of his/her treatment differ after a real-life treatment experience, compared to before treatment? |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Summary score derived from patient preferences of adverse events | Up to three months | In advanced stage NSCLC patients, is a summary score derived from patient preferences of adverse events comparable to a real-life treatment scenario? |
Other
| Measure | Time frame | Description |
|---|---|---|
| Physicians' will to select a treatment | Two years | Are physicians treating NSCLC patients more likely to select a treatment that matches patients' drug choices when provided standardized, detailed information on patients' preferences of adverse events compared to when they follow regular clinical practice? |
Countries
United States
Contacts
Primary ContactKM Munirul Islam, MD, PhD
Outcome results
None listed